Sunrun Reports First Quarter 2017 Financial Results
May 10, 2017 20:07 pm UTC| Business
Net Present Value created of $56 million in Q1 2017, an increase of 145% Year-Over-Year Net Earning Assets exceeded $1 billion, 35% Year-Over-Year Growth SAN FRANCISCO, May 10, 2017 -- Sunrun (Nasdaq:RUN), the...
Neuralstem Reports First Quarter 2017 Fiscal Results Provides Clinical and Business Update
May 10, 2017 20:07 pm UTC| Business
GERMANTOWN, Md., May 10, 2017 -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing next generation treatments for nervous system diseases, reported its financial results for the quarter ended March...
ConforMIS Reports First Quarter 2017 Financial Results
May 10, 2017 20:07 pm UTC| Business
BILLERICA, Mass., May 10, 2017 -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement...
UPDATE -- Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
May 10, 2017 20:07 pm UTC| Business
CAMBRIDGE, Mass., May 10, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its...
ConforMIS Reports First Quarter 2017 Financial Results
May 10, 2017 20:07 pm UTC| Business
BILLERICA, Mass., May 10, 2017 -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement...
miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 10, 2017 20:06 pm UTC| Business
MRG-106 granted orphan-drug status for the treatment of mycosis fungoides by U.S. Food and Drug Administration (FDA)miRagen’s collaboration with Servier extended with the objective to start testing MRG-110 in humans within...
miRagen Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
May 10, 2017 20:06 pm UTC| Business
MRG-106 granted orphan-drug status for the treatment of mycosis fungoides by U.S. Food and Drug Administration (FDA)miRagen’s collaboration with Servier extended with the objective to start testing MRG-110 in humans within...